kurskvestЧеловек и его здоровьеHumans and their health1998-57461998-5754Kursk State Medical University10.21626/vestnik/2020-3/01kurskvest-840Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEУникальные цитопротективные свойства ребамипида: обзор фундаментальных и клинических исследованийUnique cytoprotective properties of Rebamipide: review of basic and clinical researchhttps://orcid.org/0000-0002-7770-428XТригубАнастасия ВладимировнаTrigubAnastasia V.

ассистент кафедры внутренних болезней ФПО

Assistant of the Department of Internal Diseases of the Faculty of Postgraduate Education

anastasiavtrigub@yandex.ruhttps://orcid.org/0000-0001-5672-9341СтепченкоАлександр АлександровичStepchenkoAleksandr A.

д-р мед. наук, профессор, профессор кафедры внутренних болезней ФПО, декан ФПО

DM, Professor, Professor of the Department of Internal Diseases of the Faculty of Postgraduate Education, Dean of the Faculty of Postgraduate Education

therapy-fpo@mail.ruКурский государственный медицинский университетРоссияKursk State Medical UniversityRussian Federation20202109202103410Copyright © Тригуб А.В., Степченко А.А., 20212021Тригуб А.В., Степченко А.А.Trigub A.V., Stepchenko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.kursk-vestnik.ru/jour/article/view/840

В статье представлены современные экспериментальные и клинические данные по эффективности и безопасности применения препарата ребамипид в терапии эрозивно-язвенных поражений желудочно-кишечного тракта (ЖКТ), в том числе вызванных инфекцией Helicobacter pylori, приемом нестероидных противовоспалительных препаратов (НПВП), аспирином, эндоскопической подслизистой диссекцией по поводу раннего рака желудка. Долгое время единственным средством медикаментозной профилактики этих осложнений были ингибиторы протонной помпы (ИПП). Однако ИПП эффективны лишь для профилактики и лечения патологии верхних отделов ЖКТ, но не патологии тонкой кишки. При НПВП гастро- и энтеропатиях целесообразно использовать препараты, способные повышать продукцию простагландинов и слизи, восстанавливать проницаемость кишечного эпителия, оказывать противовоспалительные и антиоксидантные эффекты. Сегодня у врачей появился новый инструмент защиты слизистой оболочки ЖКТ - ребамипид. Данный препарат является уникальным цитопротектором, который стимулирует продукцию эндогенных простагландинов и гликопротеинов слизи, ингибирует реактивные формы кислорода, продукцию воспалительных цитокинов и хемокинов, ингибирует активацию нейтрофилов. Кроме того, ребамипид стимулирует синтез эпидермального фактора роста, фактора роста эндотелия сосудов, оксида азота. Указанные свойства позволяют использовать его в различных областях медицины: гастроэнтерологии, офтальмологии, химиотерапии, ревматологии, эндоскопии. В настоящее время ведутся активные разработки по созданию новых лекарственных форм препарата и поиску новых терапевтических мишеней. Целью настоящего исследования стало проведение анализа имеющихся публикаций о клинических и экспериментальных исследованиях эффективности и безопасности применения ребамипида в терапии широкого спектра патологических состояний.

The article presents current experimental and clinical data on the effectiveness and safety of the use of the drug Rebamipide in the therapy of erosive and ulcerative lesions of the gastrointestinal tract (GIT), including those caused by Helicobacter pylori infection, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, endoscopic submucosal dissection for early gastric cancer For a long time, proton pump inhibitors (PPIs) were the only means of drug prevention of these complications. However, PPIs are effective only for the prevention and treatment of pathology of the upper gastrointestinal tract, but not for pathology of the small intestine. With NSAIDs, gastro- and enteropathies, it is advisable to use drugs that can increase the production of prostaglandins and mucus, restore the permeability of the intestinal epithelium, and have anti-inflammatory and antioxidant effects. Today, doctors have a new instrument for protecting the gastrointestinal mucosa - Rebamipide. This drug is a unique cytoprotector that stimulates the production of endogenous prostaglandins and mucus glycoproteins, inhibits reactive oxygen species, the production of inflammatory cytokines and chemokines, and inhibits the activation of neutrophils. In addition, Rebamipide stimulates the synthesis of epidermal growth factor, vascular endothelial growth factor, and nitric oxide. These properties make it possible to use it in various fields of medicine: gastroenterology, ophthalmology, chemotherapy, rheumatology, and endoscopy. Currently, active developments are underway to create new dosage forms of the drug and search for new therapeutic targets. The aim of this study was to analyze the available publications on clinical and experimental studies of the efficacy and safety of using Rebamipide in the treatment of a wide range of pathological conditions.

ребамипидцитопротекторпростагландиныцитокиныгастропатияэнтеропатияRebamipidecytoprotectorprostaglandinscytokinesgastropathyenteropathyReferencesЗахарова Н. Ингибиторы протонной помпы с позиции эффективности и безопасности. Врач. 2013;10:11-14Захарова Н. Ингибиторы протонной помпы с позиции эффективности и безопасности. Врач. 2013;10:11-14Abdel-Wahab B.A., Ali F.E.M, Alkahtani S.A, Alshabi A.M, Mahnashi M.H, Hassanein E.H.M. Hepatoprotective effect of rebamipide against methotrexate-induced hepatic intoxication: role of Nrf2/GSK-3β, NF-κβ-p65/JAK1/STAT3, and PUMA/Bax/Bcl-2 signaling pathways. Immunopharmacol Immunotoxicol. 2020;42(5):493-503. DOI: 10.1080/08923973.2020.1811307Abdel-Wahab B.A., Ali F.E.M, Alkahtani S.A, Alshabi A.M, Mahnashi M.H, Hassanein E.H.M. Hepatoprotective effect of rebamipide against methotrexate-induced hepatic intoxication: role of Nrf2/GSK-3β, NF-κβ-p65/JAK1/STAT3, and PUMA/Bax/Bcl-2 signaling pathways. Immunopharmacol Immunotoxicol. 2020;42(5):493-503. DOI: 10.1080/08923973.2020.1811307Akagi S., Fujiwara T., Nishida M., Okuda A., Nagao Y., Okuda T., Tokuda H., Takayanagi K. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. DOI: 10.1186/s40780-019-0146-2Akagi S., Fujiwara T., Nishida M., Okuda A., Nagao Y., Okuda T., Tokuda H., Takayanagi K. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. DOI: 10.1186/s40780-019-0146-2Feily A., Rasaii S., Nilforoushzadeh M.A. Rebamipide as a novel addition to the antivitiligo ordnance. Int J Clin Pharmacol Ther. 2015;53(12):1035-1036. DOI: 10.5414/CP202393Feily A., Rasaii S., Nilforoushzadeh M.A. Rebamipide as a novel addition to the antivitiligo ordnance. Int J Clin Pharmacol Ther. 2015;53(12):1035-1036. DOI: 10.5414/CP202393Fukui K., Yachi K., Yoshida H., Tanji K., Matsumiya T., Hayakari R., Tsuruga K., Tanaka H. et al. Rebamipide reduces amyloid-β 1-42 (Aβ42) production and ameliorates Aβ43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells. Neurosci Res. 2017;124:40-50. DOI: 10.1016/j.neures.2017.05.005Fukui K., Yachi K., Yoshida H., Tanji K., Matsumiya T., Hayakari R., Tsuruga K., Tanaka H. et al. Rebamipide reduces amyloid-β 1-42 (Aβ42) production and ameliorates Aβ43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells. Neurosci Res. 2017;124:40-50. DOI: 10.1016/j.neures.2017.05.005Fujimoto A., Uraoka T., Nishizawa T., Shimoda M., Goto O., Ochiai Y., Maehata T., Akimoto T. et al. Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection. Gastrointest Endosc. 2018;87(4):1114-1120. DOI: 10.1016/j.gie.2017.09.040Fujimoto A., Uraoka T., Nishizawa T., Shimoda M., Goto O., Ochiai Y., Maehata T., Akimoto T. et al. Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection. Gastrointest Endosc. 2018;87(4):1114-1120. DOI: 10.1016/j.gie.2017.09.040Gweon T.-G., Park J.-H., Kim B.-W., Choi Y.K., Kim J.S., Park S.M., Kim C.W., Kim H.-G. et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018;12(1):46-50. DOI: 10.5009/gnl17078Gweon T.-G., Park J.-H., Kim B.-W., Choi Y.K., Kim J.S., Park S.M., Kim C.W., Kim H.-G. et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018;12(1):46-50. DOI: 10.5009/gnl17078Han X., Jiang K., Wang B., Zhou L., Chen X., Li S. Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-673. DOI: 10.1007/s40261-015-0329-zHan X., Jiang K., Wang B., Zhou L., Chen X., Li S. Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-673. DOI: 10.1007/s40261-015-0329-zIzawa T., Hutami I. R., Tanaka E. Potential Role of Rebamipide in Osteoclast Differentiation and Mandibular Condylar Cartilage Homeostasis. Curr Rheumatol Rev. 2018;14(1):62-69. DOI: 10.2174/1573397113666171017113441Izawa T., Hutami I. R., Tanaka E. Potential Role of Rebamipide in Osteoclast Differentiation and Mandibular Condylar Cartilage Homeostasis. Curr Rheumatol Rev. 2018;14(1):62-69. DOI: 10.2174/1573397113666171017113441Jin-Sil P., Sun-Hee H., Seung-Cheon Y., Jeong-Won C., Kyung-Ah J., Mi-La C., Sung-Hwan P. Immune modulation by rebamipide in a mouse model of Sjogren's syndrome via T and B cell regulation. Immunol Lett. 2019;214:1-7. DOI: 10.1016/j.imlet.2019.07.005Jin-Sil P., Sun-Hee H., Seung-Cheon Y., Jeong-Won C., Kyung-Ah J., Mi-La C., Sung-Hwan P. Immune modulation by rebamipide in a mouse model of Sjogren's syndrome via T and B cell regulation. Immunol Lett. 2019;214:1-7. DOI: 10.1016/j.imlet.2019.07.005Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T., Matsumoto H., Manabe N., Ito M., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. DOI: 10.1155/2015/865146Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T., Matsumoto H., Manabe N., Ito M., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. DOI: 10.1155/2015/865146Kase S., Shinohara T., Kase M., Ishida S. Effect of topical rebamipide on goblet cells in the lid wiper of human conjunctiva. Exp Ther Med. 2017;13(6):3516-3522. DOI: 10.3892/etm.2017.4390Kase S., Shinohara T., Kase M., Ishida S. Effect of topical rebamipide on goblet cells in the lid wiper of human conjunctiva. Exp Ther Med. 2017;13(6):3516-3522. DOI: 10.3892/etm.2017.4390Kim J.-W., Jeong Y., Park S.-J., Jin H., Lee J., Ju J. H., Ji G.E., Park S.-H. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford). 2020;keaa316. DOI: 10.1093/rheumatology/keaa316Kim J.-W., Jeong Y., Park S.-J., Jin H., Lee J., Ju J. H., Ji G.E., Park S.-H. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford). 2020;keaa316. DOI: 10.1093/rheumatology/keaa316Kim T.J., Kim E.R., Hong S.N., Kim Y.-H., Lee Y.C., Kim H.S., Kim K., Chang D.K. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696. DOI: 10.1038/s41598-019-48173-6Kim T.J., Kim E.R., Hong S.N., Kim Y.-H., Lee Y.C., Kim H.S., Kim K., Chang D.K. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9(1):11696. DOI: 10.1038/s41598-019-48173-6Kohata Y., Nakahara K., Tanigawa T., Yamagami H., Shiba M., Watanabe T., Tominaga K., Fujiwara Y. et al. Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett's Esophagus in a Rat Model. Dig Dis Sci. 2015;60(9):2654-2661. DOI: 10.1007/s10620-015-3662-4Kohata Y., Nakahara K., Tanigawa T., Yamagami H., Shiba M., Watanabe T., Tominaga K., Fujiwara Y. et al. Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett's Esophagus in a Rat Model. Dig Dis Sci. 2015;60(9):2654-2661. DOI: 10.1007/s10620-015-3662-4Kondo S., Mizuno S., Hashita T., Iwao T., Matsunaga T. Using human iPS cell-derived enterocytes as novel in vitro model for the evaluation of human intestinal mucosal damage. Inflamm Res. 2018;67(11-12):975-984. DOI: 10.1007/s00011-018-1193-0Kondo S., Mizuno S., Hashita T., Iwao T., Matsunaga T. Using human iPS cell-derived enterocytes as novel in vitro model for the evaluation of human intestinal mucosal damage. Inflamm Res. 2018;67(11-12):975-984. DOI: 10.1007/s00011-018-1193-0Koyama N., Sasabe H., Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002;32(7):573-586. DOI: 10.1080/0049825021013059Koyama N., Sasabe H., Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002;32(7):573-586. DOI: 10.1080/0049825021013059Kurata S., Nakashima T., Osaki T., Uematsu N., Shibamori M., Sakurai K., Kamiya S. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015;56(1):20-27. DOI: 10.3164/jcbn.14-67Kurata S., Nakashima T., Osaki T., Uematsu N., Shibamori M., Sakurai K., Kamiya S. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015;56(1):20-27. DOI: 10.3164/jcbn.14-67Lai Y., Zhong W., Yu T., Xia Z.-S., Li J.-Y., Ouyang H., Shan T.-D., Yang H.-S., Chen Q.-K. Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin. PLoS One. 2015;10(7):e0132031. DOI: 10.1371/journal.pone.0132031Lai Y., Zhong W., Yu T., Xia Z.-S., Li J.-Y., Ouyang H., Shan T.-D., Yang H.-S., Chen Q.-K. Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin. PLoS One. 2015;10(7):e0132031. DOI: 10.1371/journal.pone.0132031Min H., Kim J. Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulaiting Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis. J Trans Med. 2016;14(1):190. DOI: 10.1186/s12967-016-0942-5Min H., Kim J. Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulaiting Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis. J Trans Med. 2016;14(1):190. DOI: 10.1186/s12967-016-0942-5Murakami I., Zhang R., Kubo M., Nagaoka K., Eguchi E., Ogino K. Rebamipide suppresses mite-induced asthmatic responses in NC/Nga mice. Am J Physiol Lung Cell Mol Physiol. 2015;309(8):L872-L878. DOI: 10.1152/ajplung.00194.2015Murakami I., Zhang R., Kubo M., Nagaoka K., Eguchi E., Ogino K. Rebamipide suppresses mite-induced asthmatic responses in NC/Nga mice. Am J Physiol Lung Cell Mol Physiol. 2015;309(8):L872-L878. DOI: 10.1152/ajplung.00194.2015Nagai N., Seiriki R., Deguchi S., Otake H., Hiramatsu N., Sasaki H., Yamamoto N. Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis. Pharmaceutics. 2020;12(6):532. DOI: 10.3390/pharmaceutics12060532Nagai N., Seiriki R., Deguchi S., Otake H., Hiramatsu N., Sasaki H., Yamamoto N. Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis. Pharmaceutics. 2020;12(6):532. DOI: 10.3390/pharmaceutics12060532Narala A., Guda S., Veerabrahma K. Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. AAPS PharmSciTech. 2019;20(1):26. DOI: 10.1208/s12249-018-1225-7Narala A., Guda S., Veerabrahma K. Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. AAPS PharmSciTech. 2019;20(1):26. DOI: 10.1208/s12249-018-1225-7Nishizawa T., Suzuki H., Nakagawa I., Minegishi Y., Masaoka T., Iwasaki E., Hibi T. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259-262. DOI: 10.1159/000213241Nishizawa T., Suzuki H., Nakagawa I., Minegishi Y., Masaoka T., Iwasaki E., Hibi T. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259-262. DOI: 10.1159/000213241Ohguchi T., Kojima T., Ibrahim O.M., Nagata T., Shimizu T., Shirasawa T., Kawakita T., Satake Y., Tsubota K., Shimazaki J., Ishida S. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Invest Ophthalmol Vis Sci. 2013;54(12):7793-7802. DOI: 10.1167/iovs.13-13128Ohguchi T., Kojima T., Ibrahim O.M., Nagata T., Shimizu T., Shirasawa T., Kawakita T., Satake Y., Tsubota K., Shimazaki J., Ishida S. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Invest Ophthalmol Vis Sci. 2013;54(12):7793-7802. DOI: 10.1167/iovs.13-13128Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y., Tanaka F., Kamata N. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28. DOI: 10.1159/000452356Otani K., Tanigawa T., Watanabe T., Shimada S., Nadatani Y., Nagami Y., Tanaka F., Kamata N. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28. DOI: 10.1159/000452356Pittayanon R., Piyachaturawat P., Rerknimitr R., Prueksapanich P., Chaitongrat S., Lertsuwunseri V., Srimahachota S., Mahachai V. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019;34(9):1517-1522. DOI: 10.1111/jgh.14671Pittayanon R., Piyachaturawat P., Rerknimitr R., Prueksapanich P., Chaitongrat S., Lertsuwunseri V., Srimahachota S., Mahachai V. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019;34(9):1517-1522. DOI: 10.1111/jgh.14671Proffitt C., Bidkhori G., Moyes D., Shoaie S. Disease, Drugs and Dysbiosis: Understanding Microbial Signatures in Metabolic Disease and Medical Interventions. Microorganisms. 2020;8(9):1381. DOI: 10.3390/microorganisms8091381Proffitt C., Bidkhori G., Moyes D., Shoaie S. Disease, Drugs and Dysbiosis: Understanding Microbial Signatures in Metabolic Disease and Medical Interventions. Microorganisms. 2020;8(9):1381. DOI: 10.3390/microorganisms8091381Saad S.Y., Najjar T.A., Al-Sohaibani M.O. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. J Pharmacological Research. 2000;42(1):81-86. DOI: 10.1006/phrs.2000.0662Saad S.Y., Najjar T.A., Al-Sohaibani M.O. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. J Pharmacological Research. 2000;42(1):81-86. DOI: 10.1006/phrs.2000.0662Sakane Y, Yamaguchi M. Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients. J Ophthalmol. 2019;2019:8145731. DOI: 10.1155/2019/8145731Sakane Y, Yamaguchi M. Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients. J Ophthalmol. 2019;2019:8145731. DOI: 10.1155/2019/8145731Seo G.H., Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-228. DOI: 10.1159/000495288Seo G.H., Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-228. DOI: 10.1159/000495288Suyama Y., Handa O., Naito Y., Takayama S., Mukai R., Ushiroda C., Majima A., Yasuda-Onozawa Y. et al. Mucus reduction promotes acetyl salicylic acid-induced small intestinal mucosal injury in rats. Biochem Biophys Res Commun. 2018;498(1):228-233. DOI: 10.1016/j.bbrc.2018.02.202Suyama Y., Handa O., Naito Y., Takayama S., Mukai R., Ushiroda C., Majima A., Yasuda-Onozawa Y. et al. Mucus reduction promotes acetyl salicylic acid-induced small intestinal mucosal injury in rats. Biochem Biophys Res Commun. 2018;498(1):228-233. DOI: 10.1016/j.bbrc.2018.02.202Tsukamoto H., Mizoshita T., Katano T., Hayashi N., Ozeki K., Ebi M., Shimura T., Mori Y. et al. Preventive effect of rebamipide on N-methyl-N′-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-277. DOI: 10.1016/j.etp.2015.01.003Tsukamoto H., Mizoshita T., Katano T., Hayashi N., Ozeki K., Ebi M., Shimura T., Mori Y. et al. Preventive effect of rebamipide on N-methyl-N′-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-277. DOI: 10.1016/j.etp.2015.01.003Watanabe T., Takeuchi T., Handa O., Sakata Y., Tanigawa T., Shiba M., Naito Y., Higuchi K. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One. 2015;10(4):e0122330. DOI: 10.1371/journal.pone.0122330Watanabe T., Takeuchi T., Handa O., Sakata Y., Tanigawa T., Shiba M., Naito Y., Higuchi K. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One. 2015;10(4):e0122330. DOI: 10.1371/journal.pone.0122330Yan B., Lu Z., Ge Z., Liu S., Guo X., Tian D., Yang Y., Li X. et al. A Multicenter, Randomized, Controlled Trial of Rebamipide Plus Lansoprazole for the Treatment of Postendoscopic Submucosal Dissection Ulcers. Clin Transl Gastroenterol. 2019;10(1):e00008. DOI: 10.14309/ctg.0000000000000008Yan B., Lu Z., Ge Z., Liu S., Guo X., Tian D., Yang Y., Li X. et al. A Multicenter, Randomized, Controlled Trial of Rebamipide Plus Lansoprazole for the Treatment of Postendoscopic Submucosal Dissection Ulcers. Clin Transl Gastroenterol. 2019;10(1):e00008. DOI: 10.14309/ctg.0000000000000008Yasuda-Onozawa Y., Handa O., Naito Y., Ushiroda C., Suyama Y., Toyokawa Y., Murakami T., Yasuda T. et al. Rebamipide upregulates mucin secretion of intestinal goblet cells via Akt phosphorylation. Mol Med Rep. 2017;16(6):8216-8222. DOI: 10.3892/mmr.2017.7647Yasuda-Onozawa Y., Handa O., Naito Y., Ushiroda C., Suyama Y., Toyokawa Y., Murakami T., Yasuda T. et al. Rebamipide upregulates mucin secretion of intestinal goblet cells via Akt phosphorylation. Mol Med Rep. 2017;16(6):8216-8222. DOI: 10.3892/mmr.2017.7647Zakaria S., Alaa E.-S. Rebamipide retards CCl4-induced hepatic fibrosis in rats: Possible role for PGE2. J Immunotoxicol. 2016;13(4):453-462. DOI: 10.3109/1547691X.2015.1128022Zakaria S., Alaa E.-S. Rebamipide retards CCl4-induced hepatic fibrosis in rats: Possible role for PGE2. J Immunotoxicol. 2016;13(4):453-462. DOI: 10.3109/1547691X.2015.1128022

The authors declare that there are no conflicts of interest present.